Banque Pictet & Cie SA Decreases Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Banque Pictet & Cie SA reduced its position in shares of BioNTech SE (NASDAQ:BNTX) by 5.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,070 shares of the company’s stock after selling 110 shares during the period. Banque Pictet & Cie SA’s holdings in BioNTech were worth $236,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Planning Capital Management Corp lifted its position in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the last quarter. Blue Trust Inc. lifted its position in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the last quarter. GAMMA Investing LLC lifted its position in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after acquiring an additional 300 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new stake in BioNTech in the third quarter valued at $210,000. Finally, Sanctuary Advisors LLC purchased a new stake in BioNTech in the second quarter valued at $223,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BNTX has been the subject of a number of research reports. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target for the company. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. HC Wainwright restated a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Wells Fargo & Company initiated coverage on shares of BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective on the stock. Finally, Berenberg Bank initiated coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Trading Down 2.4 %

Shares of BioNTech stock opened at $119.83 on Friday. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company’s 50-day simple moving average is $117.22 and its 200-day simple moving average is $109.45. The firm has a market cap of $28.73 billion, a price-to-earnings ratio of -57.06 and a beta of 0.17.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.